Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:advocates_for |
informed consent required
|
| gptkbp:analysis |
statistical analysis
|
| gptkbp:analyzes |
Dr. Javier Cortés
trastuzumab emtansine |
| gptkbp:business_model |
obtained from ethics committees
|
| gptkbp:clinical_trial |
published in peer-reviewed journals
other HE R2-targeted therapies NC T00829166 |
| gptkbp:collaborations |
multiple research institutions
|
| gptkbp:collection |
clinical assessments
|
| gptkbp:completed |
gptkb:2013
|
| gptkbp:criteria |
HE R2-positive status
prior treatment with T-D M1 |
| gptkbp:end_date |
December 2013
|
| gptkbp:ends_at |
trastuzumab emtansine improves outcomes
|
| gptkbp:events |
approximately 2 years
|
| gptkbp:focuses_on |
HE R2-positive breast cancer
|
| gptkbp:followed_by |
ongoing studies
|
| gptkbp:future_plans |
exploration of combination therapies
|
| https://www.w3.org/2000/01/rdf-schema#label |
EMILIA trial
|
| gptkbp:impact |
advancement in breast cancer treatment
|
| gptkbp:is_compared_to |
lapatinib plus capecitabine
|
| gptkbp:is_protected_by |
parallel assignment
|
| gptkbp:is_studied_in |
multicenter study
interventional study |
| gptkbp:is_tested_for |
Phase III
|
| gptkbp:launch_date |
January 2010
|
| gptkbp:launched |
gptkb:2010
|
| gptkbp:location |
multiple countries
|
| gptkbp:notable_work |
improved progression-free survival
|
| gptkbp:participants |
overall survival
progression-free survival |
| gptkbp:population |
adult female patients
|
| gptkbp:provides_information_on |
influenced treatment guidelines
data available upon request |
| gptkbp:published_year |
gptkb:2014
|
| gptkbp:receives_funding_from |
gptkb:Company
|
| gptkbp:recorded_by |
randomized controlled trial
|
| gptkbp:result |
gptkb:The_Lancet
2012 ASCO Annual Meeting |
| gptkbp:side_effect |
serious adverse events
|
| gptkbp:sponsor |
gptkb:Roche
|
| gptkbp:status |
completed
|
| gptkbp:student_enrollment |
approximately 980 patients
|
| gptkbp:target_audience |
patients with metastatic breast cancer
|
| gptkbp:treatment |
trastuzumab emtansine and control
|
| gptkbp:vision |
open-label study
|
| gptkbp:year |
gptkb:2012
|
| gptkbp:bfsParent |
gptkb:Trastuzumab_emtansine
|
| gptkbp:bfsLayer |
6
|